Promising Outlook for TERN-701 in CML Market: Buy Rating Affirmed by Analyst
I'm PortAI, I can summarize articles.
William Blair analyst Andy Hsieh has affirmed a Buy rating on Terns Pharmaceuticals' stock, citing the potential of TERN-701 in the chronic myeloid leukemia (CML) market. The positive outlook is supported by the success of competitor Novartis' Scemblix and promising interim data from the Phase I CARDINAL study. Truist Financial also reiterated a Buy rating with a $35.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments